Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132627) titled 'Efficacy, Safety, and Pharmacokinetics of Belumosudil Mesylate in Pediatric Patients with Chronic Graft-Versus-Host Disease' on Sept. 16.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine
Condition:
Chronic graft-versus-host disease (cGVHD) developing after allogeneic hematopoietic stem cell transplantation.
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-10-01
Target Sample Size: Belumosudil Mesylate treatment group:120;
Countries of Recruitment:
China
To know...